Revance Therapeutics, Inc.

Dendreon Corporation

Leland Stanford Junior University

Anosys, Inc.

Curtis L Ruegg

Jacob M Waugh

Reiner Laus

Stewart A Thompson

Hongran Fan Stone

Hongyu Wu

Edgar George Engleman

Michael H Shapero

Henry G Lamparski

Demao Yang

Jean-Bernard Le Pecq

Jenq Yuan Yao

Di-Hewi Hsu

Alberto Rivas

Sunita Babbar

Hongran F Stone

This invention provides methods to treat or prevent cervical dystonia, a disorder related thereto, or a symptom thereof, with novel injectable compositions comprising botulinum toxin that may be administered to a subject suffering from such maledy. The injectable compositions and methods in which these compositions are used provide novel and advantageous treatments which result in high responder rates and long duration of effect, for example, a duration of effect for 24 weeks and longer.

Methods of treatment for cervical dystonia

The present invention provides methods, compositions, and kits for treating bladder disorders or conditions, in which botulinum toxin is topically administered to the mucosal inner lining or urothelium of the bladder, of a subject in need thereof, for transmucosal delivery across the urothelium to surrounding bladder wall musculature and/or neuronal tissue. Rather than requiring injection, the toxin instead may be administered by instillation in solution via the urethra. In particular, the botulinum toxin is administered in conjunction with a positively charged or lipophilic carrier comprising a positively charged polymeric backbone or a hydrophobic backbone with covalently attached groups that enhance transmucosal transport across the urothelium and may also stabilize the botulinum toxin in aqueous formulations.

Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders

This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.

Albumin-free botulinum toxin formulations

This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.

Injectable botulinum toxin formulations

Methods and systems for chromatographically purifying aneurotoxin are provided. These methods and systems allow for efficient purification of a non-complexed form of theneurotoxin in high purity and yield that can be used as an active ingredient in pharmaceutical preparations.

Methods and systems for purifying non-complexedneurotoxin

This invention relates totoxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using suchtoxin formulations.

Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purifiedneurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery ofneurotoxin to the nasal anatomy for the treatment of rhinitis.

Compositions and methods for safe treatment of rhinitis

Methods and systems for purifying non-complexed botulinum neurotoxin

Disclosed are a novel prostatic acid phosphatase and corresponding coding region derived from mouse. Also disclosed is a method of producing an immune response against an autologous polypeptide tumor antigen by immunizing a subject with a xenogeneic polypeptide antigen, either alone, as part of a viral antigen construct, or as part of a pulsed dendritic cell preparation.

Composition and method for producing an immune response against tumor-related antigens

The present invention relates to methods of preparing biological material, for use in various experimental, diagnostic or therapeutic uses, including immunotherapy treatment or prophylaxy of tumors. More particularly, the present invention relates to methods of preparing membrane vesicles (in particular exosomes) released by various types of mammalian cells, comprising diafiltration and/or density cushion centrifugation. The invention also provides novel methods for characterizing and analyzing exosome preparations, which can be used in quality control assay for the purpose of pharmaceutical product production. The invention is suitable to produce pharmaceutical grade preparations of such membrane vesicles and to fully characterize said preparations, for use in human beings.

Methods of producing membrane vesicles

Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.

Growing community of inventors

Redwood City, CA, United States of America

Curtis L Ruegg